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Abstract
Zika virus (ZIKV), transmitted by Aedes species mosquitoes, was first isolated in Uganda in 1947. 
From February 2014 to October 2017, the Uganda Virus Research Institute, in collaboration with 
the US Centers for Diseases Control and Prevention, conducted arbovirus surveillance in acute 
febrile illness (AFI) patients at St Francis hospital in Nkonkonjeru. Three hundred and eighty-four 
serum samples were collected and tested for IgM antibodies to yellow fever virus (YFV), West 
Nile virus (WNV), dengue virus (DENV), chikungunya virus (CHIKV) and ZIKV. Of the 384 
samples, 5 were positive for ZIKV IgM. Of these five, three were confirmed by plaque reduction 
neutralization test (PRNT) to be ZIKV infections. Of the remaining two, one was determined to be 
a non-specific flavivirus infection and one was confirmed to be alphavirus-positive by reverse 
transcriptase polymerase chain reaction (RT-PCR). This study provides the first evidence of 
laboratory-confirmed ZIKV infection in Uganda in five decades, and emphasizes the need to 
enhance sentinel surveillance.
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Zika virus (ZIKV), family Flaviviridae, genus flavivirus, is transmitted by Aedes species 
mosquitoes, including Aedes aegypti and Aedes albopictus [1]. ZIKV was first isolated in 
Uganda from a rhesus monkey in 1947 [2], and a short time later was first identified in 
humans in Nigeria [3]. Only a few human cases of ZIKV infection were reported before the 
21st century [4–9], when in 2007 a large outbreak occurred on the island of Yap [10]. In 
2016, a widespread outbreak occurred in South America, marking the first time the virus 
was known to be transmitted in the Americas [11–13] and resulting in microcephaly in 
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newborns [14], Guillain–Barré syndrome [15] and viral meningoencephalitis [16]. Sexual 
transmission has also been reported for ZIKV infections [17]. Because of its global 
distribution and ability to cause birth defects, the World Health Organization (WHO) 
declared the ZIKV epidemic in the Americas to be a Public Health Emergency of 
International Concern (PHEIC) in 2016 [18].
Studies have reported Uganda as a hotspot for many viral infections [19, 20], and recent 
studies reported the presence of ZIKV transmission-competent mosquito vectors throughout 
Uganda [21–23], a nation with environmental conditions conducive to the spread of 
arboviruses, including ZIKV. Here we report serological evidence of ZIKV infection in 
patients presenting with acute febrile illness (AFI) in a health facility in central Uganda. 
This study was facilitated through the arbovirus surveillance programme at the Uganda 
Virus Research Institute (UVRI), in collaboration with the Division of Vector-Borne 
Diseases (DVBD) of the US Centers for Disease Control and Prevention (CDC).
The Department of Arbovirology, Emerging and Re-emerging Infectious Diseases at UVRI 
established sentinel hospital-based surveillance to obtain clinical public health data 
concerning the causes of acute febrile illness (AFI) throughout the year. All patients enrolled 
in the study had a documented temperature of ≥37.5 °C or a reported history of fever 
without an identified source that had persisted for 2–7 days. Other symptoms included 
headache, chills, or muscle and joint pains. Serum samples were collected from patients at 
the St Francis Hospital Nkokonjeru sentinel site (Nkokonjeru sentinel site, 0°14′ 22.0″ N, 
32° 55′ 23.0″ E; 50 kilometres southeast of Kampala). Samples were collected from 
February 2014 to October 2017, stored frozen in liquid nitrogen tanks and shipped monthly 
to the Arbovirology Laboratory at the UVRI in Entebbe. At the UVRI, samples were divided 
into three aliquots, one each for serological testing, virus isolation and storage.
A total of 384 serum samples were collected and stored as described above. Heat-inactivated 
sera were tested for IgM antibodies using the CDC immunoglobulin M (IgM) antibody 
capture enzyme-linked immunosorbent assay (CDC MAC-ELISA) [24] for ZIKV and YFV 
and the InBios West Nile Detect IgM Capture ELISA, the DENV Detect IgM Capture 
ELISA and the CHIKjj Detect IgM ELISA for WNV, DENV and CHIKV, respectively 
(InBios International, Inc., Seattle, WA, USA). Of the 384 samples tested for IgM antibodies 
by ELISA, 28 tested positive for antibodies to one virus: CHIKV, 19; ZIKV, 5; YFV, 2; 
DENV, 1; and WNV, 1 (Table 1, shaded). Note that for the YFV and ZIKV IgM MAC-
ELISA, a P/N between two and three is normally considered to be equivocal and requires 
additional testing. For our purpose, since additional testing was performed on all equivocal 
and positive samples, they are listed as positive. One additional DENV equivocal result 
obtained from a CHIKV IgM-positive sample was not resolved upon retesting (Table 1, 
ARBO1208UVRI). Virus isolation on vero cell monolayers was attempted on all samples, 
but yielded no isolates after 14 days in culture.
None of the five ZIKV IgM-positive samples demonstrated cross-reactivity to the other 
viruses tested (Table 1). The five ZIKV IgM-positive samples were further tested for specific 
neutralizing antibodies to ZIKV (MR766), YFV (Couma), WNV (Eg101) and DENV-1–4 
(ChimeriVax dengue virus 1–4) by plaque reduction neutralization test (PRNT) as described 
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previously [25]. Three ZIKV IgM-positive samples were confirmed by PRNT, as determined 
by fourfold or greater increase in the reciprocal sample dilution resulting in 90 % 
neutralization relative to all other viruses tested. The neutralizing titres for the acute samples 
ranged from 1 : 160 to 1 : 2560 (Table 2). A convalescent serum sample was obtained from 
one ZIKV IgM-positive patient 4 weeks after the first acute sample was taken. The 
convalescent sample further exhibited a fourfold or greater increase in ZIKV neutralizing 
antibody titre relative to the acute sample. Clinically, two of these cases presented with 
intense fatigue, anorexia, muscle pain, joint pain and headache, while one only had fever, 
abdominal pain and hiccups (Table 3). None had clinical symptoms of vomiting, 
conjunctivitis, skin rash or retroorbital pain. The cause of infection in two of the five ZIKV 
IgM-positives could not be distinguished by PRNT. Sample ARB01279 did not neutralize 
any of the viruses tested and thus was reported as an unspecified flavivirus infection.
Among the 384 specimens tested, a single sample tested positive for more than one virus. 
ARB01120 demonstrated a fourfold greater neutralization titre against ZIKV than the 
viruses tested, although the titre was low, suggesting a previous infection. This sample was 
also positive for alphavirus RNA by reverse transcriptase polymerase chain reaction (RT-
PCR) testing using group-specific primers; attempts to further identify the RNA by 
subsequent RT-PCR testing using CHIKV, onyong-nyong and Semliki Forest virus-specific 
primers [26] returned negative results. This sample may represent a ZIKV/alphavirus co-
infection, but despite the observed fourfold difference, the low ZIKV PRNT titre is more 
likely indicative of a past infection with ZIKV or another flavivirus than an acute flavivirus 
infection. Recent surveillance for arboviruses in mosquitoes resulted in the isolation of 
Babanki virus, genus Alphavirus, from Nkokonjeru, and Usutu virus, genus Flavivirus, from 
nearby Jinja [27].
It is likely that ZIKV has circulated continuously at a low level in Uganda, but due in part to 
a lack of ZIKV surveillance among symptomatic individuals, this is the first time that human 
ZIKV infection has been reported in Uganda in more than 50 years. ZIKV infection was last 
reported in the country in 1964 in a 28-year-old European male who had lived in Uganda for 
2.5 months before the onset of illness with headache, rash and fever [5]. With the ongoing 
ZIKV circulation in South and North America, the question has been raised as to whether 
ZIKV is still circulating in Uganda. This study provides evidence of the continued 
circulation of ZIKV in Uganda.
PRNT confirmed ZIKV as the cause of infection in three out of five presumptive IgM-
positive cases. Neutralizing patient serum exhibited a greater than fourfold increase in the 
neutralization of ZIKV compared to other flaviviruses. Extensive IgM cross-reactions 
frequently occur in ELISA testing where patients have been exposed to alternative or 
previous flavivirus infection or vaccination [28]. This suggests that differential PRNT should 
be included in the routine laboratory testing algorithm, because ZIKV versus DENV results 
are crucial for guiding the clinical management of patients and public health prevention 
efforts. However, we report here confirmed ZIKV infection in a country without a high 
historical DENV circulation.
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This study has some limitations. Most importantly, the number of ZIKV cases identified 
likely underestimates the true number that occurred. Despite the dramatic birth defects 
associated with ZIKV infection in newborns, in healthy adults ZIKV infection is generally 
thought to produce mild illness. Since this was a hospital-based serosurvey, any 
asymptomatic infections or infections producing symptoms not severe enough to warrant 
hospitalization would not have been included in the survey. Despite this limitation, the 
hospital-based surveillance system has proven useful in providing information regarding the 
occurrence of arbovirus infections in this region, and in establishing a baseline for 
comparison with future AFI and arbovirus surveillance.
The cause of the infection could not be determined conclusively by PRNT in two of the five 
ZIKV IgM ELISA-positive cases. Using group-specific RT-PCR, we identified one of the 
cases as an acute unidentified alphavirus infection. As with other arbovirus infections, RT-
PCR can detect acute ZIKV infections, provided that serum is collected within the first few 
days of illness, and when positive, RT-PCR clarifies interpretation of the results [29]. 
Molecular methods, however, increase the cost of testing, and serum must be stored at −80 
°C immediately after collection to prevent viral RNA degradation. In addition, it is more 
difficult to establish and maintain the required technical capacity in low- and middle-income 
hospitals and public health laboratories. Therefore, it would not be possible to perform 
routine molecular testing for ZIKV surveillance at most African public health laboratories. 
Similarly, virus isolation testing can provide a clear result, but requires a high-quality patient 
serum specimen that must be collected relatively early in infection and stored/shipped on 
liquid nitrogen or dry ice. The majority of hospital and public health laboratories in Uganda 
do not have the capacity to perform the virus isolation procedure or to characterize any 
viruses isolated.
The results of our study indicate that the current laboratory-based arbovirus surveillance 
system in Uganda should be enhanced to include routine laboratory testing confirmation of 
hospitalized non-malaria AFI cases and enrol more hospitals and health centres in order to 
further monitor disease incidence and the trends of mosquito-borne viruses. This would 
provide an opportunity, when possible, to differentiate ZIKV infections from AFIs caused by 
infections with other viruses. In order to identify regional differences, the most appropriate 
arbovirus surveillance strategy would be nationwide surveillance with reporting of clinical 
AFI cases, with selected sentinel hospital sites at which specimens can be collected and sent 
for arbovirus testing. With limited resources to set up specialized surveillance sites, and with 
the caveat that cases not requiring hospitalization would be missed, hospitals are the most 
appropriate choice for sentinel sites.
In conclusion, this study provides evidence of ZIKV infection occurring in patients 
presenting with AFI at a hospital in Nkokonjeru, Uganda. Future expansion of the hospital 
sentinel surveillance system will provide continued disease burden information, facilitating 
the monitoring of trends in arbovirus infections throughout the country.
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Table 3.
Symptoms exhibited by patients confirmed with Zika virus infection The empty cells indicate the patient did 
not exhibit that symptom.
Symptoms ARB01034 ARB01119 ARB01129
Fever X X X
Date of illness onset Not reported 04/01/2017 03/25/2017
Vomiting/nausea
Intense fatigue/general weakness X X
Anorexia/loss of appetite X X
Abdominal pain X X X
Chest pain X X
Muscle pain X X
Joint pain X X
Headache X X
Cough X
Jaundice X
Conjunctivitis
Skin rash
Hiccups X
Pain behind eye
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